Advertisement

#Lenvima

FDA Approves Lenvima Plus Keytruda for Advanced Kidney Cancer

Targeted therapy and immunotherapy combination doubles response rate for people with advanced renal cell carcinoma.

Immunotherapy Plus Targeted Drug Combination Improves Kidney Cancer Survival

First-line Lenvima plus Keytruda yields better overall survival for patients with metastatic kidney cancer.

Lenvima Plus Keytruda Shows Promise for Advanced Liver Cancer

Nearly half of patients treated with the combination saw their tumors shrink in an early study.

Top 10 Cancer Treatment Highlights of 2019

U.S., Australia and Canada Simultaneously Approve Combo for Endometrial Cancer

Keytruda plus Lenvima is first approval under Project Orbis collaboration.

New Meds for Liver Cancer

Cabometyx is the third liver cancer drug approved in the past six months.

Lenvima

Advertisement